Evidence map›Paper›PMID 32423175›Full record

ReviewInternational journal of molecular sciences2020

Overview of Dual-Acting Drug Methotrexate in Different Neurological Diseases, Autoimmune Pathologies and Cancers.

Przemysław Koźmiński, Paweł Krzysztof Halik, Raphael Chesori, Ewa Gniazdowska

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
150citing papers in PubMed, 2 pooled it
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

150 citing papers in PubMed, 2 syntheses or guidelines pooled it, 307 citations in OpenAlex.

  1. Exposure to Antineoplastic Drugs in Occupational Settings: A Systematic Review of Biological Monitoring Data.International journal of environmental research and public health · 2022
    Pooled it
  2. Pooled it
  3. Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for oral mucositis prevention in pediatric patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

90 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Przemysław KoźmińskiCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Paweł Krzysztof HalikCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0003-0657-3793
Raphael ChesoriCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.
Ewa GniazdowskaCentre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland.ORCID 0000-0001-7446-1115
Instytut Chemii i Techniki Jądrowej · PL

Funding

Institute of Nuclear Chemistry and Technology, Warsaw, Poland This research was funded by statutory activity
6 · The paper itself

Abstract

Methotrexate, a structural analogue of folic acid, is one of the most effective and extensively used drugs for treating many kinds of cancer or severe and resistant forms of autoimmune diseases. In this paper, we take an overview of the present state of knowledge with regards to complex mechanisms of methotrexate action and its applications as immunosuppressive drug or chemotherapeutic agent in oncological combination therapy. In addition, the issue of the potential benefits of methotrexate in the development of neurological disorders in Alzheimer's disease or myasthenia gravis will be discussed.

Indexed as

Autoimmune DiseasesFolic AcidHumansMethotrexateNeoplasmsNervous System DiseasesPharmaceutical PreparationsFolic AcidMethotrexatePharmaceutical PreparationsAlzheimer’s diseaseanticancer drugdisease modifying anti-rheumatic drugimmunosuppressive drugmethotrexatemyasthenia gravis

Identifiers

PMID32423175
PMCPMC7279024
OpenAlexW3024378081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.